Desferrioxamine-chelatable iron in iron-overloaded patients
| Group . | Total number . | % DCI (+) samples . | Average of DCI (+) (μM) . | Range of DCI (+) (μM) . |
|---|---|---|---|---|
| Thalassemia major (TL)* | 16 | 91 | 4.9 | 1.7-8.6 |
| Thalassemia major (IL)* | 11 | 69 | 5.3 | 1.5-6.9 |
| HHC (Portugal)† | 30 | 9 | 0.6 | 0.4-1.1 |
| HHC (NL) | 9 | 0 | — | — |
| Controls‡ | 48 | 0 | — | — |
| Group . | Total number . | % DCI (+) samples . | Average of DCI (+) (μM) . | Range of DCI (+) (μM) . |
|---|---|---|---|---|
| Thalassemia major (TL)* | 16 | 91 | 4.9 | 1.7-8.6 |
| Thalassemia major (IL)* | 11 | 69 | 5.3 | 1.5-6.9 |
| HHC (Portugal)† | 30 | 9 | 0.6 | 0.4-1.1 |
| HHC (NL) | 9 | 0 | — | — |
| Controls‡ | 48 | 0 | — | — |
DCI indicates desferrioxamine-chelatable iron; TL, Thailand; IL, Israel; HHC,hereditary hemochromatosis; NL, Netherlands.
Sera from patients with transfusional iron overload, predominantly β-thalassemic children in Israel, and non–transfusion-dependent βE Hb adults in Thailand.
Sera from Portuguese hemochromatosis patients (Oporto area) sampled over a period of several months (1-5 samples per patient, total of 86) during a course of venesection treatment. Calculation of % DCI (+) samples was done on a pool of all of the results.
Randomly selected serum samples from non–Fe-overloaded individuals. All values of < 0.3 μM were taken as negative.